Aptevo Therapeutics Inc.

NasdaqCM:APVO Stock Report

Market Cap: US$3.9m

Aptevo Therapeutics Management

Management criteria checks 3/4

Aptevo Therapeutics' CEO is Marvin White, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is $873.45K, comprised of 64.7% salary and 35.3% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $441.30. The average tenure of the management team and the board of directors is 2.8 years and 8.3 years respectively.

Key information

Marvin White

Chief executive officer

US$873.4k

Total compensation

CEO salary percentage64.7%
CEO tenure8.3yrs
CEO ownership0.01%
Management average tenure2.8yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

May 26

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Dec 02

Aptevo gets $50/share takeout offer from shareholder Tang

Nov 18

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Nov 09

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

CEO Compensation Analysis

How has Marvin White's remuneration changed compared to Aptevo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$27m

Dec 31 2023US$873kUS$565k

-US$19m

Sep 30 2023n/an/a

-US$18m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

US$17m

Dec 31 2022US$1mUS$565k

US$7m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$6m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$3mUS$565k

-US$29m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$971kUS$498k

-US$31m

Sep 30 2020n/an/a

-US$33m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$974kUS$547k

-US$43m

Sep 30 2019n/an/a

-US$48m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$1mUS$565k

-US$54m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$34m

Mar 31 2018n/an/a

-US$35m

Dec 31 2017US$1mUS$543k

-US$33m

Compensation vs Market: Marvin's total compensation ($USD873.45K) is above average for companies of similar size in the US market ($USD648.89K).

Compensation vs Earnings: Marvin's compensation has been consistent with company performance over the past year.


CEO

Marvin White (62 yo)

8.3yrs

Tenure

US$873,446

Compensation

Mr. Marvin L. White has been an Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Marvin White
President8.3yrsUS$873.45k0.011%
$ 441.3
Jeffrey Lamothe
Executive VP & COO1.7yrsUS$741.59k0.0087%
$ 335.6
SoYoung Kwon
Senior VP3.3yrsUS$654.73k0.0060%
$ 230.7
Daphne Taylor
Senior VP & CFO1.7yrsno data0.0043%
$ 166.1
Dirk Huebner
Chief Medical Officer2.8yrsno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Management: APVO's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marvin White
President8.3yrsUS$873.45k0.011%
$ 441.3
Daniel Abdun-Nabi
Independent Director8.3yrsUS$73.21k0.0021%
$ 79.7
Zsolt Harsanyi
Independent Director8.3yrsUS$93.21k0.0021%
$ 80.5
John Niederhuber
Independent Chairman8.3yrsUS$88.21k0.0016%
$ 62.3
Barbara Kunz
Independent Director8.3yrsUS$78.21k0.0015%
$ 56.9
Grady Grant
Independent Director8.3yrsUS$70.71k0.0015%
$ 56.9

8.3yrs

Average Tenure

68.5yo

Average Age

Experienced Board: APVO's board of directors are considered experienced (8.3 years average tenure).